VR Logo

Sigilon Therapeutics Inc. (SGTX) download report


Healthcare | Biotechnology & Pharma Research

Sigilon Therapeutics Inc. (SGTX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases.

IPO Date: 04-Dec-2020

Pres, CEO & Director: Dr. Rogerio Vivaldi Coelho M.B.A., M.D., MBA

Co-Founder & Member of Scientific Advisory Board: Dr. Daniel G. Anderson Ph.D.

Listing: NASDAQ: SGTX

Country: United States

Headquarters: Cambridge, MA

Website: https://www.sigilon.com

Key Facts

Market cap: $24.79 Mln

Revenue (TTM): $5.16 Mln

Earnings (TTM): $-72.20 Mln

Cash: $103.11 Mln

Total Debt: $32.27 Mln

Insider's Holding: 21.83%

Liquidity: Low

52 Week range: $0.73 - 10.65

Shares outstanding: 32,399,300

Stock Performance

Time Period Sigilon Therapeutics (SGTX) S&P BSE Sensex* S&P Small-Cap 600*
YTD-72.28-8.62-18.78
1 month-5.32-4.54-8.00
3 months-47.96-10.19-13.65
1 Year-92.871.43-17.19
3 Years--10.146.10
5 Years--11.265.87
10 Years--11.829.84
As on 01-Jul-2022 *As on 04-Jul-2022
Year Sigilon Therapeutics (SGTX) S&P Small-Cap 600 S&P BSE Sensex
2021-94.2525.2721.99